Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | PDE5A | O76074 | 3/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14305260 | 0.95 | HTT (0.36) | CD274HPGDPDE5AABL1ALDH1A1 | |
| SCHEMBL4878870 | 0.90 | PDE5A (0.42) | CD274HPGDPDE5AKDM4EALDH1A1 | |
| SCHEMBL4867746 | 0.90 | ALDH1A1 (0.40) | HPGDPDE5AABL1KDM4EALDH1A1 | |
| SCHEMBL4877105 | 0.90 | ALDH1A1 (0.40) | HPGDPDE5AABL1KDM4EALDH1A1 | |
| SCHEMBL4877164 | 0.89 | AVPR1B (0.44) | HPGDKDM4EALDH1A1HSD17B10POLB | |
| SCHEMBL4870567 | 0.89 | CD274 (0.45) | CD274HPGDPDE5AABL1KDM4E | |
| SCHEMBL4874956 | 0.88 | ALDH1A1 (0.40) | HPGDPDE5AABL1KDM4EALDH1A1 | |
| SCHEMBL4876068 | 0.86 | ALDH1A1 (0.38) | HPGDKDM4EALDH1A1HSD17B10POLB | |
| SCHEMBL4870574 | 0.85 | MTOR (0.31) | CD274ALDH1A1RPS6KB1AKT1 | |
| SCHEMBL4877243 | 0.85 | KDM4E (0.38) | HPGDABL1KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | CD274 4210/4885HPGD 2973/4885PDE5A 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.